Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Tarik Asselah(Inserm), Fabien Zoulim(Université Claude Bernard Lyon 1), T.V. Stepanova(Université Claude Bernard Lyon 1), Marie‐Noëlle Hilleret(Université Claude Bernard Lyon 1), Ştefan Lazăr(Université Claude Bernard Lyon 1), Marc Bourlière(Universität Hamburg), Pavel Bogomolov(Université Claude Bernard Lyon 1), Renée-Claude Mercier(Université Claude Bernard Lyon 1), Gheorghe Plăcintă(Université Claude Bernard Lyon 1), Adrian Streinu‐Cercel(Université Claude Bernard Lyon 1), V. Е. Syutkin(Université Claude Bernard Lyon 1), Olga Sagalova(Université Claude Bernard Lyon 1), Dmitry Manuilov(Université Claude Bernard Lyon 1), Vlad Ratziu(Inserm), Victor Pântea(Université Claude Bernard Lyon 1), Grace M. Chee(Université Claude Bernard Lyon 1), George Sebastian Gherlan(Université Claude Bernard Lyon 1), Audrey Lau(Université Claude Bernard Lyon 1), Ben L. Da(Université Claude Bernard Lyon 1), Lei Ye(Université Claude Bernard Lyon 1), Pietro Lampertico(University of Milan), Stanislas Pol(Université Claude Bernard Lyon 1), Heiner Wedemeyer(Université Claude Bernard Lyon 1), Vladimir Chulanov(Université Claude Bernard Lyon 1), Viacheslav Morozov(Université Claude Bernard Lyon 1), Anu Osinusi(Gilead Sciences (United States))
Cited by 77
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789
Endpoints and clinical trial design for nonalcoholic steatohepatitis
|Hepatology|2011|757